Ovarian hyperstimulation syndrome

Fertility and Sterility

Volumn 82, Issue SUPPL. 1, 2004, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN; ANTIEMETIC AGENT; CHORIONIC GONADOTROPIN; DEXTRAN; DIURETIC AGENT; EPIDERMAL GROWTH FACTOR; FRESH FROZEN PLASMA; FUROSEMIDE; GONADORELIN AGONIST; GONADOTROPIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUPRORELIN; MANNITOL; PLATELET DERIVED GROWTH FACTOR; POLYSTYRENESULFONATE SODIUM; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADULT RESPIRATORY DISTRESS SYNDROME; AGE DISTRIBUTION; ANGIOGENESIS; ASCITES; BODY WEIGHT; CAPILLARY PERMEABILITY; CLINICAL TRIAL; CORPUS LUTEUM FUNCTION; DIALYSIS; DIURESIS; DRUG HYPERSENSITIVITY; ECHOCARDIOGRAPHY; ESTROGEN BLOOD LEVEL; FLUID INTAKE; HEMOCONCENTRATION; HUMAN; HYDRATION; HYPOVOLEMIA; OUTPATIENT CARE; OVARY DISEASE; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PARACENTESIS; PRION DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THORAX RADIOGRAPHY; THROMBOEMBOLISM; WEIGHT GAIN;

EID: 4444321543     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2004.05.005     Document Type: Article

References (53)

1. Blankstein J., Shalev J., Saadon T., Kukia E.E., Rabinovici J., Pariente C., et al. Ovarian hyperstimulation syndrome prediction by number and size of preovulatory ovarian follicles. Fertil Steril. 47:1987;597-602
2. McArdle C., Siebel M., Hann L.E., Weinstein F., Taymor M. The diagnosis of ovarian hyperstimulation (OHS) the impact of ultrasound. Fertil Steril. 39:1983;464-467
3. Pride S.M., James C.S.J., Yuen B.H. The ovarian hyperstimulation syndrome. Semin Reprod Endocrinol. 8:1990;247-260
4. Tollan A., Holst N., Forsdahl F., Fadnes H.O., Oian P., Maltau J.M. Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilization. Am J Obstet Gynecol. 162:1990;554-558
5. Goldsman M.P., Pedram A., Dominguez C.E., Ciuffardi I., Levin E., Asch R.H. Increased capillary permeability induced by human follicular fluid a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril. 63:1995;268-272
6. Bergh P.A., Navot D. Ovarian hyperstimulation syndrome a review of pathophysiology. J Assist Reprod Genet. 9:1992;429-438
7. Koninckx P.R., Heyns W., Verhoeven G., Van Baelen H., Lissens W.D., et al. Biochemical characterization of peritoneal fluid in women during the menstrual cycle. J Clin Endocrinol Metab. 51:1980;1239-1244
8. Koninckx P.R., Renaer M., Brosens I.A. Origin of peritoneal fluid in women an ovarian exudation product. Br J Obstet Gynaecol. 87:1980;177-183
9. Donnez J., Langerock S., Thomas K. Peritoneal fluid volume and 17βestradiol and progesterone concentrations in ovulatory, anovulatory and postmenopausal women. Obstet Gynecol. 59:1982;687-692
10. Sealey J.E., Atlas S.A., Glorioso N., Manapat H., Laragh J.H. Cyclical secretion of prorenin during the menstrual cycle synchronization with luteinizing hormone and progesterone. Proc Natl Acad Sci USA. 82:1985;8705-8709
11. Derkx F.H., Alberda A.T., Zeilmaker G.H., Schalekamp M.A. High concentrations of immunoreactive renin, prorenin and enzymatically-active renin in human ovarian follicular fluid. Br J Obstet Gynaecol. 94:1987;4-9
12. Lightman A., Tarlatzis B.C., Rzasa P.J., Culler M.D., Caride V.J., NegroVilar A.F., et al. The ovarian renin-angiotensin system renin-like activity and angiotensin II/III immunoreactivity in gonadotropin-stimulated and unstimulated human follicular fluid. Am J Obstet Gynecol. 156:1987;808-816
13. Geva E., Jaffe R.B. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril. 74:2000;429-438
14. Levin E.R., Rosen G.F., Cassidenti D.L., Yee B., Meldrum D., Wisot A., et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest. 102:1998;1978-1985
15. McClure N., Healy D.L., Rogers P.A., Sullivan J., Beaton L., Haning R.V., et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 344:1994;235-236
16. Neulen J., Yan Z., Raczek S., Weindel K., Keek C., Weich H.A., et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 80:1995;1967-1971
17. Pellicer A., Albert C., Mercader A., Bonilla-Musoles F., Remohi J., Simon C. The pathogenesis of ovarian hyperstimulation syndrome in vivo studies investigating the role of interleukin-1β, interleukin-6, and vascular endothelial growth factor. Fertil Steril. 71:1999;482-489
18. Whelan J.G. 3rd, Vlahos N.F. The ovarian hyperstimulation syndrome. Fertil Steril. 73:2000;883-896
19. Warren R.S., Yuan H., Matli M.R., Ferrara N., Donner D.B. Induction of vascular endothelial growth factor by insulin-like growth factor I in colorectal carcinoma. J Biol Chem. 271:1996;483-488
20. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol Rev. 18:1997;4-25
21. Navot D., Relou A., Birkenfeld A., Rabinowitz R., Brzezinski A., Margalioth E.J. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 159:1988;210-215
22. Delvigne A., Demoulin A., Smitz J., Donnez J., Koinckx P., Dhont M., et al. The ovarian hyperstimulation syndrome in in-vitro fertilization a Belgian multicentric study. I. Clinical and biological features. Hum Reprod. 8:1993;1353-1360
23. MacDougall M.J., Tan S.L., Jacobs H.S. In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod. 7:1992;597-600
24. Buyalos R.P., Lee C.T. Polycystic ovary syndrome pathophysiology and outcome with in vitro fertilization. Fertil Steril. 65:1996;1-10
25. Forman R.G., Frydman R., Egan D., Ross C., Barlow D.H. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization a European series and a proposal for prevention. Fertil Steril. 53:1990;502-509
26. Mizunuma H., Andoh K., Yamada K., Takagi T., Kamijo T., Ibuki Y. Prediction and prevention of ovarian hyperstimulation by monitoring endogenous luteinizing hormone release during purified follicle-stimulating hormone therapy. Fertil Steril. 58:1992;46-50
27. Mordel N., Schenker J.G. Gonadotrophin-releasing hormone agonist and ovarian hyperstimulation syndrome in assisted reproduction. Hum Reprod. 8:1993;2009-2014
28. Haning R.V. Jr, Austin C.W., Carlson I.H., Kuzma D.L., Shapiro S.S., Zweibel W.J. Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril. 40:1983;31-36
29. Enskog A., Henriksson M., Unander M., Nilsson L., Brannstrom M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 71:1999;808-814
30. Golan A., Ron-el R., Herman A., Soffer Y., Weinraub Z., Caspi E. Ovarian hyperstimulation syndrome an update review. Obstet Gynecol Surv. 44:1989;430-440
31. Zosmer A., Katz Z., Lancet M., Konichezky S., Schwartz-Shoham Z. Adult respiratory distress syndrome complicating ovarian hyperstimulation syndrome. Fertil Steril. 47:1987;524-526
32. Abramov Y., Elchalal U., Schenker J.G. Pulmonary manifestations of severe ovarian hyperstimulation syndrome a multicenter study. Fertil Steril. 71:1999;645-651
33. Pattinson H.A., Hignett M., Dunphy B.C., Fleetham J.A. Outcome of thaw embryo transfer after cryopreservation of all embryos in patients at risk of ovarian hyperstimulation syndrome. Fertil Steril. 62:1994;1192-1196
34. Shaker A.G., Zosmer A., Dean N., Bekir J.S., Jacobs H.S., Tan S.L. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. [see comments, Fertil Steril 1997;67:587-9.] Fertil Steril. 65:1996;992-996
35. Ferraretti A.P., Gianaroli L., Magli C., Fortini D., Selman H.A., Feliciani E. Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome efficiency and safety. Hum Reprod. 14:1999;1457-1460
36. Navot D., Bergh P.A., Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies prevention and treatment. Fertil Steril. 58:1992;249-261
37. Borenstein R., Elhalah U., Lunenfeld B., Schwartz Z.S. Severe ovarian hyperstimulation syndrome a reevaluated therapeutic approach. Fertil Steril. 51:1989;791-795
38. Aboulghar M.A., Mansour R.T., Serour G.I., Amin Y. Ultrasonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syndrome. [erratum appears in Fertil Steril 1990;54:957.] Fertil Steril. 53:1990;933-935
39. Rizk B., Aboulghar M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod. 6:1991;1082-1087
40. Rinaldi M.L., Spirtos N.J. Chest tube drainage of pleural effusion correcting abdominal ascites in a patient with severe ovarian hyperstimulation syndrome a case report. [comment Fertil Steril 1995;64:1228-9.] Fertil Steril. 63:1995;1114-1117
41. Ferraretti A.P., Gianaroli L., Diotallevi L., Festi C., Trounson A. Dopamine treatment for severe ovarian hyperstimulation syndrome. [comments Hum Reprod 1992;7:1181.] Hum Reprod. 7:1992;180-183
42. Reed A.P., Tausk H., Reynolds H. Anesthetic considerations for severe ovarian hyperstimulation syndrome. Anesthesiology. 73:1990;1275-1277
43. Grochowski D., Wolczynski S., Kuczynski W., Domitrz J., Szamatowicz J., Szamatowicz M. Correctly timed coasting reduces the risk of ovarian hyperstimulation syndrome and gives good cycle outcome in an in vitro fertilization program. Gynecol Endocrinol. 15:2001;234-238
44. Al-Shawaf T., Zosmer A., Hussain S., Tozer A., Panay N., Wilson C., et al. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer a modified "coasting" strategy based on ultrasound for identification of high-risk patients. Hum Reprod. 16:2001;24-30
45. Ulug U., Bahceci M., Erden H.F., Shalev E., Ben-Shlomo I. The signicance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod. 17:2002;310-313
46. Lewitt N., Kol S., Manor D., Itskovitz-Eldor J. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome a case-control study. Hum Reprod. 11:1996;1399-1402
47. Friedman C.I., Schmidt G.E., Chang F.E., Kim M.H. Severe ovarian hyperstimulation following follicular aspiration. Am J Obstet Gynecol. 150:1984;436-437
48. Asch R.H., Ivery G., Goldsman M., Frederick J.L., Stone S.C., Balmaceda J.P. The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. [comments Hum Reprod 1994;9:753-4 and Hum Reprod 1995;10:2750-2.] Hum Reprod. 8:1993;1015-1020
49. Shoham Z., Weissman A., Barash A., Borenstein R., Schachter M., Insler V. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program a prospective, randomized, placebo-controlled study. Fertil Steril. 62:1994;137-142
50. Shalev E., Giladi Y., Matilsky M., Ben-Ami M. Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin a prospective study. Hum Reprod. 10:1995;1373-1376
51. Ng E., Leader A., Claman P., Domingo M., Spence J.E. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme. Hum Reprod. 10:1995;807-810. [comments Hum Reprod 1996;11:460-1.]
52. Ben-Chetrit A., Eldar-Geva T., Gal M., Huerta M., Mimom T., Algur N., et al. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme a randomized placebo-controlled trial. Hum Reprod. 16:2001;1880-1884
53. Aboulghar M., Evers J.H., Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2:2002;CD001302